Open AccessProstate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
Author(s) -
Susan Halabi,
Andrew J. Armstrong,
Oliver Sartor,
Johann S. de Bono,
Ellen B. Kaplan,
ChenYen Lin,
Nicole Solomon,
Eric J. Small
Publication year - 2013
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2013.50.3201
Subject(s) - medicine , cabazitaxel , docetaxel , prostate cancer , mitoxantrone , hazard ratio , prostate specific antigen , chemotherapy , prednisone , oncology , urology , proportional hazards model , enzalutamide , cancer , gynecology , androgen deprivation therapy , confidence interval , androgen receptor
Prostate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). The objective of this analysis was to evaluate post-treatment PSA kinetics as surrogates for OS in patients receiving second-line chemotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom